Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation formation, and neuron death. Such neurodegenerative diseases include spinocerebellar ataxia type 3(SCA3).提供用於減少細胞或動物中ATXN3 RNA之量或活性，且在一些實施例中減少細胞或動物中ATXN3蛋白之量的化合物、方法、及醫藥組成物。此類化合物、方法、及醫藥組成物可用於改善神經退化性疾病之至少一個症狀或標誌。此類症狀及標誌包括運動功能障礙、聚集形成、及神經元死亡。此類神經退化性疾病包括脊髓小腦失調症第三型(SCA3)。
